Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Author(s): Justin C. Brown, PhD1,2,3;Chao Ma, MS4;Qian Shi, PhD5;Charles S. Fuchs, MD, MPH6;Jeffrey Meyer, BS4;Donna Niedzwiecki, PhD7;Tyler Zemla, MS5;Felix Couture, MD8;Philip Kuebler, MD9;Pankaj Kumar, MD10;DeQuincy Lewis, MD11;Benjamin Tan, MD12;Smitha Krishnamurthi, MD13;Eileen M. O’Reilly, MD14;Anthony F. Shields, MD15;and Jeffrey A. Meyerhardt, MD, MPH4
Source: DOI: 10.1200/JCO.22.00171 Journal of Clinical Oncology 41, no. 2 (January 10, 2023) 243-254.

Dr. Anjan Patel's Thoughts

Get your patients moving, even in the adjuvant setting! Of course, a lot of bias is possible here, but there was nearly a 10% difference in cure at three years.

PURPOSE

To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer.

METHODS

We conducted a prospective cohort study nested within a randomized multicenter trial of stage III colon cancer that compared 3 versus 6 months of fluorouracil, leucovorin, and oxaliplatin with or without celecoxib. We measured recreational physical activity in the first 3 months of chemotherapy and again 6 months after completion of chemotherapy. The primary end point was DFS.

RESULTS

During a median follow-up of 5.9 years, 457 of 1,696 patients experienced disease recurrence or death. For total recreational physical activity volume, the 3-year DFS was 76.5% with < 3.0 metabolic equivalent task hours per week (MET-h/wk) and 87.1% with ≥ 18.0 MET-h/wk (risk difference [RD], 10.6%; 95% CI, 4.7 to 19.4; P < .001). For light-intensity to moderate-intensity activities, the 3-year DFS was 65.7% with 0.0 h/wk and 87.1% with ≥ 1.5 h/wk (RD, 21.4%; 95% CI, 9.2 to 37.1; P < .001). For vigorous-intensity activity, the 3-year DFS was 76.0% with 0.0 h/wk and 86.0% with ≥ 1.0 h/wk (RD, 10.0%; 95% CI, 4.5 to 18.9; P < .001). For brisk walking, the 3-year DFS was 81.7% with < 1.0 h/wk and 88.4% with ≥ 3.0 h/wk (RD, 6.7%; 95% CI, 3.0 to 13.8; P < .001). For muscle strengthening activity, the 3-year DFS was 81.8% with 0.0 h/wk and 88.8% for ≥ 0.5 h/wk (RD, 7.0%; 95% CI, 3.1 to 14.2; P = .003).

CONCLUSION

Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS.

Author Affiliations

1Pennington Biomedical Research Center, Baton Rouge, LA;2LSU Health Sciences Center New Orleans School of Medicine, New Orleans, LA;3Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA;4Dana-Farber/Partners CancerCare, Boston, MA;5Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN;6Genentech, Inc, South San Francisco, CA;7Duke University Medical Center, Durham, NC;8Hôtel-Dieu de Québec, Québec, QC, Canada;9Columbus NCI Community Oncology Research Program, Columbus, OH;10Illinois CancerCare PC, Peoria, IL;11Cone Health Medical Group, Asheboro, NC;12Siteman Cancer Center, Washington University School of Medicine in St Louis, Saint Louis, MO;13Cleveland Clinic, Cleveland, OH;14Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY;15Karmanos Cancer Institute, Wayne State University, Detroit, MI

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials

There is more movement towards using time to relapse as an endpoint for adjuvant studies. This report highlights that there is still a role for oxaliplatin in older patients with Stage III CRC. The time to relapse was not significantly different in patients who are younger vs older. TTR is suggested as a more informative endpoint as older patients uniformly have a lower DFS and OS in most trials.

Read More »